EGFR and lung carcinoma: Given the resistance to EGFR tyrosine kinase inhibitors in cMET-expressing lung cancer and the synergistic effect of cMET and EGFR inhibitors, dual targeting of EGFR and cMET is a promising therapeutic strategy.9, 10, 11